Milder chemo before stem cell transplant shows promise for rare blood disorders
NCT ID NCT04528355
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks 50 children and adults with non-malignant disorders like immune deficiencies and anemias who receive a stem cell transplant after a reduced-intensity chemotherapy regimen. The goal is to see if this approach improves survival and reduces severe graft-versus-host disease. Researchers will collect medical data from participants' charts over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stem cell transplant (umbilical cord blood, bone marrow, or peripheral blood stem cells) with reduced-intensity chemotherapy (alemtuzumab, melphalan, thiotepa, fludarabine, hydroxyurea)
- What this could lead to
- If successful, this could improve survival and reduce severe graft-versus-host disease for patients with non-malignant disorders needing a stem cell transplant.
- What could go wrong
- This is an early-stage, single-center study with only 50 participants, so results may not apply broadly. Risks include graft failure, infection, and side effects from chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL BONE MARROW FAILURE SYNDROMES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC Children's Hospital of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.